FIGURE 2.
Kaplan–Meier estimates of the incidence of end‐stage renal disease (ESRD; left) and all‐cause death (right) in patients using sodium‐glucose co‐transporter‐2 inhibitors (SGLT2 inhibitors; red) versus other glucose lowering drugs (oGLDs; black)